Brookstone Capital Management Has $12.40 Million Stock Holdings in Boston Scientific Corporation $BSX

Brookstone Capital Management lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 2.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 115,415 shares of the medical equipment provider’s stock after acquiring an additional 2,454 shares during the quarter. Brookstone Capital Management’s holdings in Boston Scientific were worth $12,397,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of BSX. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. Swedbank AB increased its stake in shares of Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after acquiring an additional 1,505,019 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the last quarter. Finally, Ninety One UK Ltd boosted its holdings in Boston Scientific by 33.5% in the second quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock worth $552,755,000 after purchasing an additional 1,290,414 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BSX. UBS Group upped their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Raymond James Financial upped their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $121.71.

Boston Scientific Stock Up 3.8%

BSX stock opened at $103.66 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a 50-day moving average of $101.22 and a two-hundred day moving average of $101.85. The stock has a market capitalization of $153.60 billion, a price-to-earnings ratio of 61.70, a price-to-earnings-growth ratio of 2.40 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the company earned $0.63 earnings per share. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 over the last ninety days. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.